Articles

The use of low molecular weight heparin (LMWH), an injectable, clot-preventing drug for patients with advanced cancer, increased steadily between 2000 and 2007, according to a new study published in The Oncologist. However, use of LMWH is low compared with another anticoagulant, warfarin, despite previous research demonstrating LMWH as the preferred treatment for patients with cancer suffering blood clots.

As a result of federal legislation, electronic health records (EHRs) are becoming an integral part of nurses’ daily practice. Now, a large study has determined the multiple benefits of implementing EHRs in the medical setting.

A study published in the Journal of Nursing Administration involved more than 16,000 nurses working at 316 hospitals in 4 states. Researchers found more improvements to nursing care and better health outcomes for patients when EHRs were in use.

Although oxaliplatin has extended the survival time of patients with colorectal cancer, the drug can also mean debilitating neurological side effects for those receiving treatments. These side effects often begin with a “pins and needles” sensation in the fingers and toes. Over time, a patient’s ability to walk or even dress independently is eventually compromised.

Breast cancer cell proliferation did not decline with the use of soy isoflavone supplements in a randomized clinical trial, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

These study results are compatible with the findings of previous studies designed to test dietary supplements and their cancer prevention benefits, said lead researcher Seema A. Khan, MD, professor of surgery at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Five different studies have successfully established the effectiveness of a blood test used for discovering and evaluating circulating tumor cells (CTCs), according to scientists from The Scripps Research Institute, Scripps Health, and other collaborating cancer physicians. The findings, published February 3, 2012, in the journal Physical Biology, show the highly sensitive blood analysis provides information that may soon be compared to the information gleaned from some types of surgical biopsies.

A new study shows PSA velocity (PSAV) risk count testing in which a man’s PSA levels are tracked over time may help doctors more accurately assess for clinically significant prostate cancer. The new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine was published online by the British Journal of Urology International on February 1, 2012.

The key to enhancing treatment for particular types of aggressive breast cancer may be the body’s control mechanisms for delivering zinc to cells.

Zinc plays a vital part in human health. However, too much or too little zinc can lead to cell death. In fact, mounting evidence associates zinc with a number of diseases, including cancer.

Monroe Township, NJ and Boston, MA, January 24, 2012 — A formal alliance known as The Lynx Group™ has been established between 4 privately owned medical communication companies each with a unique niche and expertise in the healthcare industry: Engage Healthcare Communications, Green Hill Healthcare Communications, Core Principle Solutions, and Center of Excellence Media.  
 
Read More ›

Recent findings published in the December issue of the Journal of Urology suggest the size of a man’s prostate gland may help predict the severity of cancer.

A national fast track system for cancer patients that was implemented in Denmark reduced the time between a patient’s initial meeting with a healthcare provider and their first treatment by 4 weeks, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium.